Formulations including 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide

Powder formulations for use in dry powder inhalers and methods of making them are provided. A powder formulation can include from about 0.01% to about 90% by weight of a carboxamide compound comprising 5-[3-(3-Hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2- diphenyl-hexanamide or a pharmaceutically acce...

Full description

Saved in:
Bibliographic Details
Main Authors MARCELLIN, Claire, BURROWS, Jane, MAGEE, Gavin
Format Patent
LanguageEnglish
Published 02.02.2023
Subjects
DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY
DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROMTHE BODY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Powder formulations for use in dry powder inhalers and methods of making them are provided. A powder formulation can include from about 0.01% to about 90% by weight of a carboxamide compound comprising 5-[3-(3-Hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2- diphenyl-hexanamide or a pharmaceutically acceptable salt thereof and an excipient. Another powder formulation includes in addition to the carboxamide compound or its hydrochloride salt a long acting β2 adrenoreceptor agonist and an inhalable corticosteroid.
Bibliography:Application Number: AU20210296221